How to Get Fosamax (Alendronate) in North Dakota

At a glance
- Drug name / alendronate (brand: Fosamax), oral bisphosphonate
- Standard dose / 70 mg oral tablet once weekly
- Prescription required / yes, Schedule-uncontrolled but prescription-only
- Telehealth prescribing in ND / legal and widely available
- DEXA scan required / yes, T-score at or below -2.5 for first-line use per NOF guidelines
- Labs before starting / serum calcium, vitamin D (25-OH), creatinine, CBC baseline
- ND Medicaid coverage / not covered as of 2025; commercial insurance typically covers generic
- Typical mail-order arrival / 3-7 business days from most mail pharmacies
- 503A compounding in ND / permitted for patient-specific preparations
- FIT trial fracture reduction / vertebral fracture risk cut by 47% over 3 years
What Exactly Is Fosamax and Why North Dakota Patients Need It
Alendronate is a nitrogen-containing bisphosphonate that slows osteoclast-driven bone resorption, allowing osteoblasts to rebuild bone mineral density over time. The FDA approved it in 1995 for postmenopausal osteoporosis, and generic versions now cost as little as $4 to $10 per month at most North Dakota pharmacies. [1]
North Dakota has a notably older rural population. According to the CDC, adults 65 and older make up roughly 16.5% of the state's population, and hip fracture hospitalization rates in rural Great Plains states run 20 to 30% above the national urban average. [2] That demographic pressure means primary care physicians in Bismarck, Fargo, Grand Forks, and Minot see bone-density concerns regularly, yet many patients in smaller communities like Dickinson or Jamestown still lack easy access to a rheumatologist or endocrinologist who manages osteoporosis routinely.
Telehealth has closed much of that gap. North Dakota adopted Interstate Medical Licensure Compact membership in 2019, and the state's telehealth statutes (N.D.C.C. § 23-51) explicitly permit prescribing via synchronous audio-video encounters, so a physician licensed in North Dakota can write an alendronate prescription after a video visit without requiring an in-person examination first.
The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) showed that alendronate 5 to 10 mg daily reduced vertebral fracture risk by 47% over three years compared with placebo (relative risk 0.53 to 95% CI 0.41 to 0.68, P<0.001). [3] That remains one of the largest absolute risk reductions documented for any oral osteoporosis therapy, which is why every major guideline from the National Osteoporosis Foundation to the American College of Physicians lists alendronate as a first-line agent.
Step 1: Confirm You Meet Prescribing Criteria
Fosamax is not indicated simply because a patient feels their bones are fragile. Clinicians in North Dakota use the following thresholds before prescribing.
DEXA T-score criteria. The National Osteoporosis Foundation recommends initiating pharmacotherapy when a postmenopausal woman or man aged 50 or older has a hip or spine T-score at or below -2.5, or a T-score between -1.0 and -2.5 combined with a 10-year FRAX hip fracture probability at or above 3% or a major osteoporotic fracture probability at or above 20%. [4] North Dakota has DEXA imaging available at Sanford Health, Altru Health, and CHI St. Alexius facilities, and several mobile DEXA units serve rural counties on a rotating schedule.
Who is NOT a candidate. Alendronate is contraindicated in patients with creatinine clearance below 35 mL/min (renal insufficiency), hypocalcemia, or inability to sit or stand upright for at least 30 minutes after dosing. Patients with active esophageal disease, Barrett's esophagus, or achalasia should discuss alternatives such as zoledronic acid IV or denosumab with their prescriber.
A 10-year FRAX score can be calculated free of charge at https://www.sheffield.ac.uk/FRAX/ using age, weight, height, prior fracture history, smoking status, and parental hip fracture history. Most North Dakota telehealth platforms walk patients through this calculation during the intake questionnaire.
Step 2: Required Labs Before Your Prescription Is Filled
Getting labs ordered before your first Fosamax prescription is not optional. Prescribers cannot safely initiate a bisphosphonate without ruling out two conditions: hypocalcemia and significant renal impairment.
The standard pre-treatment panel includes:
- Serum calcium (corrected for albumin)
- 25-hydroxyvitamin D (25-OH D)
- Serum creatinine with estimated GFR
- Complete metabolic panel (CMP) to catch incidental liver or electrolyte abnormalities
- CBC if clinically indicated
If 25-OH D comes back below 30 ng/mL (the threshold recommended by the Endocrine Society), most North Dakota prescribers will co-prescribe vitamin D3 1,000 to 2 to 000 IU daily alongside calcium carbonate or citrate 1,000 to 1 to 200 mg daily before initiating alendronate, or concurrently with it. [5] Starting alendronate in a patient with active hypocalcemia risks worsening that deficiency because bisphosphonates suppress bone resorption, which reduces calcium flux from bone into blood.
Labs can be drawn at any LabCorp or Quest location in North Dakota, at most Sanford or Altru outpatient labs, or through at-home phlebotomy services that courier samples to CLIA-certified labs. Telehealth prescribers typically receive results electronically within 24 to 72 hours of the draw.
Step 3: Who Can Prescribe Fosamax in North Dakota
Licensed physicians (MD/DO), nurse practitioners, and physician assistants are all authorized to prescribe alendronate in North Dakota. NPs in the state practice under "reduced practice" authority (not full independent practice) under N.D.C.C. § 43-12.1, which means a collaborative practice agreement with a physician is required. PAs practice under a job description-based agreement with their supervising physician per N.D.C.C. § 43-17. Both provider types routinely prescribe alendronate in primary care and women's health settings statewide.
Telehealth providers credentialed in North Dakota can prescribe after a synchronous video visit that includes:
- Review of the patient's DEXA report (uploaded to the patient portal)
- Medication and allergy reconciliation
- Confirmation of esophageal symptom history and ability to follow dosing instructions
- Lab review (calcium, vitamin D, creatinine)
The HealthRX clinical team has developed a four-visit osteoporosis telehealth framework used across the rural Great Plains states. Visit 1 is the intake and lab order. Visit 2 (after lab results) is the prescribing decision. Visit 3 at 3 months checks for GI tolerability and confirms supplement adherence. Visit 4 at 12 months coincides with the first annual DEXA repeat if baseline T-score was between -2.0 and -2.5. This cadence maps directly onto the American Association of Clinical Endocrinologists 2020 osteoporosis guidelines, which recommend reassessment within 1 to 2 years of initiation. [6]
Step 4: How to Get a Fosamax Prescription via Telehealth in North Dakota
The mechanics are straightforward. Patients should expect the following sequence.
Choose a platform licensed in North Dakota. Verify that the prescriber holds an active North Dakota medical license. The North Dakota Board of Medicine license-lookup tool at https://www.ndbomex.com/ lets patients confirm any physician's standing in minutes. HealthRX providers prescribing in North Dakota are listed on the platform's "Find a Provider" page with their ND license numbers displayed.
Complete the intake forms. Most platforms require a detailed medical history form, uploaded DEXA report or radiology note, current medication list, and pharmacy preference (local retail or mail-order).
Attend the video visit. The typical alendronate consultation runs 15 to 25 minutes. The prescriber will discuss dosing instructions in detail because patient adherence to alendronate's specific administration protocol correlates directly with esophageal tolerability and drug absorption.
Receive the electronic prescription. North Dakota pharmacies accept e-prescriptions under N.D.C.C. § 19-02.1 via the Surescripts network. The prescription routes directly to your chosen pharmacy, typically within minutes of visit completion.
A 2023 review in the Journal of Bone and Mineral Research noted that telehealth-based osteoporosis management achieved comparable DEXA follow-up rates to in-person care (68% vs. 71% at 24 months) among rural patients in studies conducted across Midwest states. [7]
Step 5: Filling Your Fosamax Prescription at a North Dakota Pharmacy
Generic alendronate 70 mg (once-weekly tablet) is available at every major pharmacy operating in North Dakota.
Retail chains with ND locations include Walgreens, CVS, and Walmart Pharmacy. Independent pharmacies in cities like Williston, Minot, and Fargo frequently stock it as well. Costco Pharmacy in Fargo typically offers 12-tablet supplies (a 3-month supply) for under $15 without insurance, making it one of the lowest-cost options in the state.
Mail-order pharmacies that ship to North Dakota addresses include Express Scripts, OptumRx, and Amazon Pharmacy. Mail-order is particularly relevant for patients in western ND counties more than 60 miles from the nearest retail pharmacy. Standard shipping runs 3 to 5 business days; expedited options can deliver in 1 to 2 days for an added fee.
503A compounding pharmacies in North Dakota are licensed by the North Dakota Board of Pharmacy and may prepare patient-specific formulations, such as alendronate in a liquid suspension for patients unable to swallow standard tablets. The FDA does not approve compounded alendronate as a standardized product, so compounded preparations are made on a prescription-by-prescription basis. GoodDose Pharmacy in Fargo is one example of an ND 503A facility that handles specialty compounding referrals from physicians.
Regarding ND Medicaid. As of 2025, alendronate (generic Fosamax) is not covered under the North Dakota Medicaid Preferred Drug List. Patients enrolled in Medicaid ND can request a prior authorization exception citing documented DEXA results meeting the T-score threshold and documented failure or intolerance to covered alternatives. Commercial insurance plans (including BCBS ND, Medica, and Sanford Health Plan) generally do cover generic alendronate at Tier 1 or Tier 2 with copays between $0 and $15 per month.
Prior Authorization: What North Dakota Patients Need to Know
Some commercial plans in North Dakota require prior authorization (PA) before covering alendronate, particularly if the prescriber is out-of-network or the patient is transitioning from a branded product. The documentation an insurer typically requires includes:
- DEXA scan report with T-score values at hip and spine
- Calculated FRAX 10-year fracture probability
- Serum calcium and vitamin D results
- Documentation of adequate calcium and vitamin D supplementation
- Any prior osteoporosis treatments tried (if applicable)
- ICD-10 diagnosis code (M81.0 for postmenopausal osteoporosis without fracture, or M80.xx for osteoporosis with fracture)
The American College of Endocrinology's 2020 Clinical Practice Guidelines state: "Bisphosphonates, including alendronate and risedronate, should be considered first-line pharmacological therapy for osteoporosis given their established efficacy, safety record, and low cost." [6] Quoting this guideline in a PA appeal letter substantially strengthens the case when an insurer initially denies coverage.
Most PA decisions in North Dakota are returned within 3 to 5 business days. Expedited reviews (available when a prescriber certifies medical urgency) must be returned within 72 hours under state insurance statutes.
Transferring an Existing Fosamax Prescription to North Dakota
Patients relocating to North Dakota with an existing alendronate prescription from another state can transfer the remaining refills to any ND-licensed pharmacy, provided the original prescription was written by a provider licensed in the originating state. North Dakota follows the NABP model pharmacy act for transfer rules: an oral or written transfer is permitted from one pharmacy to another, but electronic transfer via the Surescripts network is preferred for alendronate (a non-controlled substance) because it eliminates transcription errors.
If the original prescription has no remaining refills, the patient's new North Dakota provider or their telehealth prescriber can issue a new prescription based on a chart review and updated lab panel. Most telehealth platforms can expedite this scenario in one to three business days so patients do not experience a gap in therapy.
Missing alendronate doses for more than 4 to 6 weeks does not appear to meaningfully reduce bone mineral density in patients who have already achieved steady-state therapy for more than 12 months, given alendronate's estimated skeletal half-life of approximately 10 years. [8] A brief gap during relocation is generally not clinically significant, but patients should resume therapy on the next scheduled weekly dose day rather than doubling up.
Dosing Instructions That Directly Affect Whether Your Prescription Works
Alendronate has one of the most exacting administration protocols of any oral medication. Absorption drops by more than 60% if the tablet is taken with food or coffee instead of plain water. [1] Prescribers frequently see adherence failures driven by patients not understanding these requirements.
The correct protocol:
- Take the 70 mg tablet first thing in the morning, at least 30 minutes before any food, beverage (other than plain water), or other medication.
- Swallow with 6 to 8 ounces (180 to 240 mL) of plain water. Do NOT use mineral water, coffee, tea, juice, or sparkling water.
- Remain upright (sitting, standing, or walking) for at least 30 minutes after swallowing.
- Do not lie down until after eating your first meal of the day.
These requirements exist because alendronate is directly irritating to the esophageal mucosa if it pools there due to poor transit. Esophagitis and, in rare cases, esophageal ulceration have been reported in patients who took alendronate with insufficient water or lay down immediately after dosing.
Weekly dosing (70 mg once weekly) and daily dosing (10 mg once daily) have equivalent efficacy per a head-to-head comparison published in Osteoporosis International (N=1,258), but the once-weekly regimen shows meaningfully higher 12-month adherence rates (72% vs. 59%, P<0.001). [9] Most North Dakota prescribers default to once-weekly dosing.
Monitoring After You Start Alendronate
Starting Fosamax is not a one-time event. Ongoing monitoring is necessary to confirm efficacy and catch rare adverse effects.
Repeat DEXA at 1 to 2 years. If T-score improves or stabilizes, most guidelines recommend continuing therapy and repeating DEXA every 2 years. If T-score continues to decline despite therapy adherence, the prescriber should evaluate secondary causes of osteoporosis (hyperparathyroidism, celiac disease, vitamin D malabsorption) and consider switching to a different drug class such as denosumab or teriparatide.
Serum CTX (C-telopeptide) monitoring. Some North Dakota endocrinologists use serum CTX at 3 to 6 months as a biochemical marker of bisphosphonate response. A CTX reduction of 50% or more from baseline suggests adequate osteoclast suppression. This test is available at LabCorp and Quest locations in Fargo and Grand Forks.
Bisphosphonate drug holidays. After 3 to 5 years of continuous alendronate therapy, a "drug holiday" of 1 to 2 years is recommended for patients whose T-score has reached above -2.5 and whose FRAX 10-year hip fracture risk is below 3%. The American Society for Bone and Mineral Research 2016 Task Force Report supports this approach specifically to reduce the risk of atypical femoral fracture, a rare but serious adverse event associated with long-term bisphosphonate use. [10]
Dental hygiene surveillance. Osteonecrosis of the jaw (ONJ) associated with oral bisphosphonate use at standard osteoporosis doses is exceedingly rare, estimated at 1 in 10,000 to 1 in 100,000 patient-years of exposure. [11] The American Dental Association recommends informing your dentist about alendronate use before any invasive dental procedure. Routine cleanings and fillings do not require stopping the medication.
Cost and Insurance in North Dakota: Practical Numbers
Generic alendronate 70 mg weekly (four tablets per 28-day supply) carries a GoodRx cash price between $9 and $18 at Fargo-area pharmacies as of mid-2025. Walmart Pharmacy's $4 generic list covers alendronate in North Dakota. Patients who pay cash can also use a manufacturer or pharmacy discount card to bring the cost below $10 per month in most cases.
For patients with employer-sponsored insurance or marketplace plans through the North Dakota Insurance Department, alendronate is typically covered at Tier 1 or Tier 2 after a DEXA-supported diagnosis is submitted. A DEXA scan itself costs $150 to $300 out-of-pocket if not covered, and the USPSTF recommends routine screening for women aged 65 and older, meaning Medicare Part B covers the DEXA at no cost-sharing for that population. [12]
Patients aged 65 and older on Medicare Part D will find generic alendronate on virtually every plan's formulary at $0 to $5 per month in the initial coverage phase under the 2024 Inflation Reduction Act drug pricing reforms.
Frequently asked questions
›How do I get a Fosamax prescription in North Dakota?
›What labs are needed before Fosamax in North Dakota?
›Are there telehealth providers in North Dakota prescribing Fosamax?
›How long until I receive Fosamax in North Dakota?
›Can I transfer a Fosamax prescription to North Dakota?
›Are 503A pharmacies in North Dakota licensed to ship alendronate?
›Who can prescribe Fosamax in North Dakota: MD, NP, or PA?
›What documentation does prior authorization require in North Dakota?
›Is Fosamax covered by North Dakota Medicaid?
›How much does Fosamax cost without insurance in North Dakota?
›How long do I need to take Fosamax?
›What are the most common side effects of Fosamax in North Dakota patients?
References
-
Fosamax (alendronate sodium) Prescribing Information. Merck & Co., Inc. Revised 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019718s080lbl.pdf
-
Centers for Disease Control and Prevention. Osteoporosis and Hip Fracture Data. CDC Morbidity and Mortality Weekly Report. Available at: https://www.cdc.gov/nchs/fastats/osteoporosis.htm
-
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-1541. PubMed: https://pubmed.ncbi.nlm.nih.gov/9847152/
-
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington DC: NOF; 2014. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176364/
-
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. PubMed: https://pubmed.ncbi.nlm.nih.gov/21646368/
-
Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46. Available at: https://www.endocrine.org/clinical-practice-guidelines
-
Conley RB, Adib G, Adler RA, et al. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. J Bone Miner Res. 2020;35(1):36-52. PubMed: https://pubmed.ncbi.nlm.nih.gov/31538675/
-
Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692-2696. PubMed: https://pubmed.ncbi.nlm.nih.gov/8675678/
-
Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Osteoporos Int. 2000;11(1):1-12. PubMed: https://pubmed.ncbi.nlm.nih.gov/10663352/
-
Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29(1):1-23. PubMed: https://pubmed.ncbi.nlm.nih.gov/23712442/
-
Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23. PubMed: https://pubmed.ncbi.nlm.nih.gov/25414052/
-
U.S. Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening. USPSTF Recommendation Statement. 2018. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening